.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Joe OSullivan, MD

Articles

Dr. O'Sullivan on Safety Profile of Radium-223

December 16th 2015

Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queenâ€™s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.

Dr. O'Sullivan on Radium-223 With Enzalutamide and Abiraterone in mCRPC

July 28th 2015

Joe O'Sullivan, MD, discusses the efficacy of radium-223 when combined with enzalutamide and/or abiraterone in an international early access program for the treatment of patients with metastatic castration-resistant prostate cancer.